HCV Warning For ESAs Could Raise Questions For Pipeline Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Warning on red cell aplasia and anemia for Procrit and Aranesp in hepatitis C patients could have implications for boceprevir and telaprevir.
You may also be interested in...
Anemia Not A “Deal Breaker” For Boceprevir – SPRINT-1 Study Investigator
Higher rate of anemia seen with HCV patients treated with boceprevir versus control is manageable, Schering maintains.
Anemia Not A “Deal Breaker” For Boceprevir – SPRINT-1 Study Investigator
Higher rate of anemia seen with HCV patients treated with boceprevir versus control is manageable, Schering maintains.
HCV Among Merck’s Gains With Schering, But Future Moves Still Murky
As Merck and Schering-Plough await a potential monkey wrench from Johnson & Johnson for their merger, observers are sorting through each company's partnerships for would-be redundancies